Watch CBS News

Pfizer

1219-satmo-clevelandvaccine-612774-640x360.jpg

Extra Pfizer vaccine doses spur optimism

The FDA granted emergency authorization to Moderna's vaccine. An initial batch of six million doses will begin shipping out this weekend, and Moderna says it hopes to make up to 100 million doses available in the U.S. by March. It comes one week after the approval of Pfizer’s vaccine, which is already being administered. Errol Barnett was the first to report that some vials of the Pfizer vaccine contained extra doses, and is now showing how that was enough to vaccinate even more health care workers and staff at one Cleveland hospital.

1218-cbsn-devastatedcovidvaccine-612228-640x360.jpg

Health care workers wait for Pfizer vaccine

Health care workers across the country are waiting for their hospital to receive the first round of Pfizer's coronavirus vaccine as COVID-19 surges. Meanwhile, the Food and Drug Administration is gearing up to approve emergency-use authorization for Moderna's vaccine. Dr. Kelechi Olejeme joins CBSN AM one day after receiving the Pfizer vaccine. She explained the differences between the two vaccines and how she felt following her inoculation.

cbsn-fusion-fda-panel-recommends-modernas-coronavirus-vaccine-for-emergency-use-thumbnail-611956-640x360.jpg

FDA panel endorses moderna's coronavirus vaccine

An FDA advisory panel has recommended emergency use of Moderna's coronavirus vaccine. The FDA could authorize the vaccine as early as Friday and six million doses could be shipped out next week. This comes as the total number of cases in the U.S. tops 17 million and California becomes the epicenter of the nation's outbreak. Dr. Yves Duroseau, chair of the Department of Emergency Medicine at Lenox Hill Hospital, joins CBSN to discuss how the vaccines work.

cbsn-fusion-big-pharma-pharmaceutical-companies-covid-19-vaccine-thumbnail-611336-640x360.jpg

Could Big Pharma cash in on COVID vaccine?

Pfizer and Moderna could be looking at a big check once their first round of COVID vaccines are distributed, despite a non-lucrative market and pressure to keep costs low. But the key for both companies may lie in the patenting process. Quartz reporter Annalisa Merelli joined CBSN AM to explain how the COVID vaccine compares to other vaccines on the market and why the mRNA patent could have larger implications outside of coronavirus. She also gave insight to life inside Bergamo, Italy, one of the hardest-hit town earlier on in the pandemic.

cbsn-fusion-moderna-vaccine-next-in-line-for-fda-authorization-thumbnail-610556-640x360.jpg

FDA panel to discuss Moderna vaccine Thursday

The U.S. could be days away from authorizing a second coronavirus vaccine as both coasts see cases surge. CBS News correspondent David Begnaud reports on California hospitals grappling with a rising infection rate and Dr. Neeta Ogden, internal medicine specialist and immunologist, joined CBSN to discuss the how some states are struggling with vaccine funding and the Food and Drug Administration's authorization of the first over-the-counter rapid test.

Show More
View CBS News In
CBS News App Open
Chrome Safari Continue
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.